Vimarsana
Biggest News Aggregation in the World

Page 31 - Boxed Warning News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Boxed Warning Today - Breaking & Trending Today

Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023 - Vimarsana News

Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023

– Long-Term & Real-World HIV Research Offer Insights into How Treatment with Biktarvy® and Sunlenca® May Help Inform the Future of Coordinated, Person-Centered HIV Care – – Updates on...

Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise - Vimarsana News

Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise

Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and...

Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey - Vimarsana News

Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with...

Brixadi Now Available for Weekly or Monthly Administration to Treat Opioid Use Disorder - Vimarsana News

Brixadi Now Available for Weekly or Monthly Administration to Treat Opioid Use Disorder

Brixadi® extended-release subcutaneous injection is now available for the treatment of moderate to severe opioid use disorder.

New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients - Vimarsana News

New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients

- Patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura for up to two years -...